224 related articles for article (PubMed ID: 12436385)
1. [Rivastigmine: a review of its clinical effectiveness].
Spiegel R
Rev Neurol; 2002 Nov 1-15; 35(9):859-69. PubMed ID: 12436385
[TBL] [Abstract][Full Text] [Related]
2. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
Grossberg GT
Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903
[TBL] [Abstract][Full Text] [Related]
3. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Robert P
Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
5. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine for Alzheimer's disease.
Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
[TBL] [Abstract][Full Text] [Related]
7. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH
Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746
[TBL] [Abstract][Full Text] [Related]
8. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
9. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Farlow MR
Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
11. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Doody RS
J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Rösler M
Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
[TBL] [Abstract][Full Text] [Related]
13. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA
Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333
[TBL] [Abstract][Full Text] [Related]
14. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibitors in the treatment of dementia.
Ellis JM
J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of Alzheimer's disease].
López OL; Becker JT
Rev Neurol; 2002 Nov 1-15; 35(9):850-9. PubMed ID: 12436384
[TBL] [Abstract][Full Text] [Related]
17. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
[TBL] [Abstract][Full Text] [Related]
18. Realistic expectations for treatment success in Alzheimer's disease.
Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine for Alzheimer's disease.
Desai AK; Grossberg GT
Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
[TBL] [Abstract][Full Text] [Related]
20. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
